alert22-Lancet_2007_370_1907

							       Trial profile for the pharmacokinetics and
pharmacodynamics study in patients with dyslipidaemia (A)
      and the ambulatory blood pressure study (B)




       *Participants who received drug in period 1 received placebo in period 2 and vice versa
                                                           Rajesh Krishna, et al. Lancet 2007;370:1907-14
   Change from baseline versus time profiles for serum HDL-C (A),
  LDL-C (B), apolipoprotein A-I (C), and apolipoprotein B (D) after
administration of anacetrapib or placebo to patients with dyslipidaemia




                                        Rajesh Krishna, et al. Lancet 2007;370:1907-14
Hourly mean systolic (A)
 and diastolic (B) blood
 pressure (SE) over 24 h
post-dose on day 10 after
    administration of
anacetrapib (or matching
   placebo) in healthy
 middle-aged and elderly
      people (N=22)




R. Krishna, et al. Lancet 2007;370:1907-14
 Mean ambulatory systolic and diastolic blood pressure at
24 h post-dose on day 10 after administration of anacetrapib
or placebo in healthy middle-aged and elderly people (N=22)




                                  Rajesh Krishna, et al. Lancet 2007;370:1907-14
Incidence of adverse events in patients with dyslipidaemia




                                 Rajesh Krishna, et al. Lancet 2007;370:1907-14
 Incidence of adverse events in
ambulatory blood pressure study




                   Rajesh Krishna, et al. Lancet 2007;370:1907-14